Daniel Gillet is a leading expert in diagnostic and therapeutic innovation, with over 30 years of experience studying animal and bacterial toxins. Holding two master’s degrees, a PhD, and an HDR, he was a visiting scientist at Boston University Hospital Medical Center before leading a laboratory at the CEA.

He has contributed to cancer vaccine development and advanced the atomic-scale understanding of the diphtheria toxin. He is now a global leader in broad-spectrum inhibitors against hazardous toxins and pathogens.

A former advisor to the High Commissioner for Atomic Energy, Daniel Gillet is a biodefense specialist, having coordinated research within the Joint ministerial program of R&D against CBRNE threats for 12 years and served as vice president of the Biotox Piratox laboratory network scientific committee.

His expertise spans bacterial toxin engineering (16 patents), 20+ R&D projects, and the commercialization of six industrial products. He has worked with CRO and CDMO service providers and led training programs in therapeutic innovation and biodefense, earning distinctions such as Chevalier in the Order of Academic Palms (2012) and the Silver Medal of Honor from the Military Health Service (2021).

Both scientist and strategist, he continues to shape medical research and biological security through his academic and industrial leadership.